EGFR and non-small cell lung carcinoma: However, data regarding long-term survival outcomes as well as acquired resistance are currently pending and will shed more light on whether this combination proves to be more beneficial for EGFR-mutated NSCLC patients (Clinicaltrials.gov identifier: NCT03122717).